 |
Solebury Trout is working with the investment community for Novavax, which has announced its COVID-19 vaccine has a 93 percent efficacy rate against the virus.
Stanley Erck, CEO of the Gaithersburg, MD biotech, said Novavax “is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines."
The firm plans to file for regulatory approval for its NVX-CoV2373 vaccine in the third quarter.
Once approved, Novavax said it will be able to produce 100M shots a month by the end of Q3 and 150 doses by year-end.
Novavax, which is 33 years old, has never had a vaccine approved by the Food and Drug Administration.
Solebury Trout’s Alexandria Roy represents Novavax.
Prosek Partners handles New York’s Tilray Brands, craft beer & cannabis operation, as it acquires BrewDog, a leading British independent beer producer in the UK, for $45M.
Brunswick Group handles Zurich Insurance as it agrees to buy UK-based Beazley specialty insurer in a deal valued at $11B.
FGS Global represents Brink’s as it agrees to acquire NCR Atleos, which relies on Collected Strategies, in a $6.6B cash & stock deal to create a leading fintech infrastructure company. (Updated)
A January article in O’Dwyer’s proposes that in 2026, the strongest financial brands will not simply tell compelling stories—they will “signal readiness.”
C Street Advisory Group is working the Chapter 11 filing of Axip Energy Services as it unloads its nearly all of its assets to deal with a heavy debt load.
